Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders

References

• Agyare EK, Curran GL, Ramakrishnan M, Caroline CY, Poduslo JF, Kandimalla KK. 2008. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 25:2674–2684.
   PubMed Web of Science ®Google Scholar
• Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, Fernandez-Megia E, et al. 2005. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem. 16:1503–1511.
   PubMed Web of Science ®Google Scholar
• Amano S, Ohashi M, Kirihara M, Yang XH, Hazama F. 1994. α-Tocopherol protects against radical-induced injury in cultured neurons. Neurosci Lett. 170:55–58.
   PubMed Web of Science ®Google Scholar
• Banks WA, Kastin AJ. 1990. Peptide transport systems for opiates across the blood-brain barrier. Am J Physiol Endocrinol Metab. 259:E1–E10.
   PubMed Web of Science ®Google Scholar
• Barbu E, Molnàr É, Tsibouklis J, Górecki DC. 2009. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv. 6:553–565.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. 2001. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 299: 483–493.
   PubMed Web of Science ®Google Scholar
• Begley DJ. 2004. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 104: 29–45.
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, et al. 2005. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA. 102:11539–11544.
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazú V, et al. 2010. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 7:3.
   PubMed Web of Science ®Google Scholar
• Blanchette M, Fortin D. 2011Blood-brain barrier disruption in the treatment of brain tumors. In: The Blood-Brain and Other Neural Barriers New York: Springer, pp. 447–463.
   Google Scholar
• Bodor N, Buchwald P. 1999. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev. 36:229–254.
   PubMed Web of Science ®Google Scholar
• Borlongan C, Emerich D. 2003. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 60:297–306.
   PubMed Web of Science ®Google Scholar
• Brambilla D, Souguir H, Nicolas J, Mackiewicz N, Verpillot R, Le Droumaguet B, et al. 2011. Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-β peptide. J Biotechnol. 156:338–340.
   PubMed Web of Science ®Google Scholar
• Brightman MW. 1977. Morphology of blood-brain interfaces. Exp Eye Res. 25:1–25.
   PubMed Web of Science ®Google Scholar
• Chauhan NB. 2002. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. Antisense Nucleic Acid Drug Dev. 12:353–357.
   PubMedGoogle Scholar
• Chou KJ, Donovan MD. 1998. Lidocaine distribution into the CNS following nasal and arterial delivery: a comparison of local sampling and microdialysis techniques. Int J Pharm. 171:53–61.
   Web of Science ®Google Scholar
• Cicchetti F, Drouin-Ouellet J, Gross RE. 2009. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. 30:475–483.
   PubMed Web of Science ®Google Scholar
• Cosco D, Paolino D, Muzzalupo R, Celia C, Citraro R, Caponio D, et al. 2009. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevices. 11:1115–1125.
   PubMed Web of Science ®Google Scholar
• Czeisler BM, Janigro D. 2006. Reading and writing the blood-brain barrier: relevance to therapeutics. Recent Pat CNS Drug Discov. 1:157–173.
   PubMedGoogle Scholar
• De Boer A, Gaillard P. 2007. Drug targeting to the brain. Annu Rev Pharmacol Toxicol. 47:323–355.
   PubMed Web of Science ®Google Scholar
• Demeule M, Poirier J, Jodoin J, Bertrand Y, Desrosiers RR, Dagenais C, et al. 2002. High transcytosis of melanotransferrin (P97) across the blood–brain barrier. J Neurochem. 83:924–933.
   PubMed Web of Science ®Google Scholar
• Douglas SJ, Davis SS, Illum L. 1986. Biodistribution of poly (butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm. 34:145–152.
   Web of Science ®Google Scholar
• Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M. 2003. Alkylglycerol opening of the blood–brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol. 140:1201–1210.
   PubMed Web of Science ®Google Scholar
• Ferrante R, Kowall N, Beal M, Richardson E, Bird E, Martin J. 1985. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 230:561–563.
   PubMed Web of Science ®Google Scholar
• Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. 2000. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm. 49: 103–109.
   PubMed Web of Science ®Google Scholar
• Furumoto K, Nagayama S, Ogawara K, Takakura Y, Hashida M, Higaki K, Kimura T. 2004. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release. 97:133–141.
   PubMed Web of Science ®Google Scholar
• Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. 2006. Lectin-conjugated PEG–PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials. 27:3482–3490.
   PubMed Web of Science ®Google Scholar
• Gil-Mohapel J, Simpson JM, Ghilan M, Christie BR. 2011. Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies? Brain Res. 1406:84–105.
   PubMed Web of Science ®Google Scholar
• Godinho BM, Ogier JR, Darcy R, O’Driscoll CM, Cryan JF. 2013. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol Pharm. 10:640–649.
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science. 263:1600–1603.
   PubMed Web of Science ®Google Scholar
• Harmon BT, Aly AE, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL. 2014. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther. 21:514–521.
   PubMed Web of Science ®Google Scholar
• Hebert LE, Beckett LA, Scherr PA, Evans DA. 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 15:169–173.
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 60:1119–1122.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci. 95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. 2011. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Int J Phar. 415:273–283.
   PubMed Web of Science ®Google Scholar
• Huang R, Ke W, Liu Y, Wu D, Feng L, Jiang C, Pei Y. 2010. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 290:123–130.
   PubMed Web of Science ®Google Scholar
• Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, et al. 2013. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson's disease. Pharma Res. 30:2549–2559.
   Web of Science ®Google Scholar
• Huong NT, Giang LTK, Binh NT. 2009. Surface modification of iron oxide nanoparticles and their conjuntion with water soluble polymers for biomedical application. J Phys. 012046.
   Google Scholar
• Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, Sheikov N. 2006. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg. 105:445–454.
   PubMed Web of Science ®Google Scholar
• Ilium L, Hunneyball I, Davis S. 1986. The effect of hydrophilic coatings on the uptake of colloidal particles by the liver and by peritoneal macrophages. Int J Pharm. 29:53–65.
   Google Scholar
• Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1:297.
   PubMed Web of Science ®Google Scholar
• Jalali N, Moztarzadeh F, Mozafari M, Asgari S, Motevalian M, Alhosseini SN. 2011. Surface modification of poly (lactide-co-glycolide) nanoparticles by d-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain. Colloids Surf A Physicochem Eng Asp. 392:335–342.
   Web of Science ®Google Scholar
• Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. 2012. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 8:250–260.
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L. 2008. The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today. 13:1099–1106.
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. 2013. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials. 34:9220–9226.
   PubMed Web of Science ®Google Scholar
• Karanth H, Murthy RSR. 2008. Nanotechnology in brain targeting. Int J Pharm Sci Nanotechnol. 1:9–24.
   Google Scholar
• Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D, et al. 2007. Translocation of poly (ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules. 8:793–799.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 2004. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 4:484–488.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 47:65–81.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. 1995. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171–174.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. 2007. Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release. 118:54–58.
   PubMed Web of Science ®Google Scholar
• Lazar AN, Mourtas S, Youssef I, Parizot C, Dauphin A, Delatour B, et al. 2013. Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine. 9:712–721.
   PubMed Web of Science ®Google Scholar
• Leu D, Manthey B, Kreuter J, Speiser P, Deluca PP. 1984. Distribution and elimination of coated polymethyl [2‐14C] methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci. 73:1433–1437.
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. 2011. Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 32:4943–4950.
   PubMed Web of Science ®Google Scholar
• Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. 2010. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials. 31:7340–7354.
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. 2006. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett. 406:189–193.
   PubMed Web of Science ®Google Scholar
• Liu YY, Yang XY, Li Z, Liu ZL, Cheng D, Wang Y, et al. 2014. Characterization of polyethylene glycol‐polyethyleneimine as a vector for alpha‐synuclein siRNA delivery to PC12 cells for Parkinson's disease. CNS Neurosci Ther. 20:76–85.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiang M, Kang T, Miao D, Gu G, Song Q, et al. 2013. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials. 34:3870–3881.
   PubMed Web of Science ®Google Scholar
• Maccioni RB, Muñoz JP, Barbeito L. 2001. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 32:367–381.
   PubMed Web of Science ®Google Scholar
• Malhotra M, Tomaro-Duchesneau C, Prakash S. 2013. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 34:1270–1280.
   PubMed Web of Science ®Google Scholar
• Mansur AA, Saliba JB, Mansur HS. 2013. Surface modified fluorescent quantum dots with neurotransmitter ligands for potential targeting of cell signaling applications. Colloids Surf B Biointerfaces. 111: 60–70.
   PubMed Web of Science ®Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, et al. 2006. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol ExpTher. 317:1246–1253.
   PubMed Web of Science ®Google Scholar
• Mittal G, Carswell H, Brett R, Currie S, Kumar M. 2011. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J Control Release. 150:220–228.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53:283–318.
   PubMed Web of Science ®Google Scholar
• Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, van Vuuren S, et al. 2013. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm. 448:267–281.
   PubMed Web of Science ®Google Scholar
• Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, et al. (2008). Strategies to advance translational research into brain barriers. Lancet Neurol. 7:84–96.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA. 1989Implications of the Blood-brain Barrier and Its Manipulation New York: Plenum Pub Corp.
   Google Scholar
• Ogawara K, Furumoto K, Takakura Y, Hashida M, Higaki K, Kimura T. 2001. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J Control Release. 77:191–198.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Terasaki T. 2007. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res. 24:1745–1758.
   PubMed Web of Science ®Google Scholar
• Olivier V, Meisen I, Meckelein B, Hirst TR, Peter-Katalinic J, Schmidt MA, Frey A. 2003. Influence of targeting ligand flexibility on receptor binding of particulate drug delivery systems. Bioconjug Chem. 14:1203–1208.
   PubMed Web of Science ®Google Scholar
• Paolino D, Cosco D, Racanicchi L, Trapasso E, Celia C, Iannone M, et al. 2010. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZARZ Biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release. 144:144–150.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. 2013. Novel surface modified polymer–lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 24:2101–2115.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 1988. Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol. 28:25–39.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2002. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today. 7:5–7.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2006. Molecular Trojan horses for blood–brain barrier drug delivery. Curr opin Pharmacol. 6:494–500.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2007. Blood–brain barrier delivery. Drug Discov Today. 12:54–61.
   PubMed Web of Science ®Google Scholar
• Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. 2009. Getting into the brain. CNS Drugs. 23:35–58.
   PubMed Web of Science ®Google Scholar
• Peracchia M, Fattal E, Desmaele D, Besnard M, Noel J, Gomis J, et al. 1999. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 60:121–128.
   PubMed Web of Science ®Google Scholar
• Peracchia MT, Vauthier C, Desmaële D, Gulik A, Dedieu J-C, Demoy M, et al. 1998. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res. 15:550–556.
   PubMed Web of Science ®Google Scholar
• Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. 2007. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release. 117:51–58.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:2045–2047.
   PubMed Web of Science ®Google Scholar
• Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, et al. 2012. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials. 33:7194–7205.
   PubMed Web of Science ®Google Scholar
• Rautioa J, Chikhale PJ. 2004. Drug delivery systems for brain tumor therapy. Curr Pharm Des. 10:1341–1353.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC. 2002. Lessons from animal models of Huntington's disease. Trends Genet. 18:202–209.
   PubMed Web of Science ®Google Scholar
• Smith QR. 1993Drug delivery to brain and the role of carrier-mediated transport In: Frontiers in Cerebral Vascular Biology. New York: Springer, pp. 83–93.
   Google Scholar
• Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. 1997. α-synuclein in lewy bodies. Nature. 388:839–840.
   PubMed Web of Science ®Google Scholar
• Su Y, Sinko PJ. 2006. Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it? Expert Opin Drug Deliv. 3:419–435.
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. 2000. Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci. 89:1371–1388.
   PubMed Web of Science ®Google Scholar
• Temsamani J, Scherrmann JM, Rees AR, Kaczorek M. 2000. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm Sci Technolo Today. 3:155–162.
   PubMedGoogle Scholar
• Torchilin V. 1998. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul. 15:1–19.
   PubMed Web of Science ®Google Scholar
• Tröster S, Kreuter J. 1988. Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly (methyl methacrylate) surfaces. Int J Pharm. 45:91–100.
   Web of Science ®Google Scholar
• Tröster S, Müller U, Kreuter J. 1990. Modification of the body distribution of poly (methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm. 61:85–100.
   Web of Science ®Google Scholar
• van Laar T, Van der Geest R, Danhof M. 1999. Future delivery systems for apomorphine in patients with Parkinson's disease. Adv Neurol. 80:535–544.
   PubMedGoogle Scholar
• Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. 2003. Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev. 55:519–548.
   PubMed Web of Science ®Google Scholar
• Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, et al. 2012. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PloS One. 7:e32568.
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, et al. 2011. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release. 151:131–138.
   PubMed Web of Science ®Google Scholar
• Wu H, Li J, Zhang Q, Yan X, Guo L, Gao X, et al. 2012. A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid-β25–35-treated rats following intranasal administration. Eur J Pharm Biopharm. 80:368–378.
   PubMed Web of Science ®Google Scholar
• Xin H, Sha X, Jiang X, Chen L, Law K, Gu J, et al. 2012. The brain targeting mechanism of Angiopep-conjugated poly (ethylene glycol)-co-poly (ɛ-caprolactone) nanoparticles. Biomaterials. 33: 1673–1681.
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, et al. 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release. 137:78–86.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q, Qian Y. 2014. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials. 35:456–465.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Q, Zha L, Yang W, Wang C, Jiang X, Fu S. 2004. Preparation, characterization and application of pyrene-loaded methoxy poly (ethylene glycol)–poly (lactic acid) copolymer nanoparticles. Colloid Polym Sci. 282:1323–1328.
   Web of Science ®Google Scholar
• Zhou J. 2010. Recent progress in neurodegenerative disorder research in China. Sci China Life Sci. 53:348–355.
   PubMed Web of Science ®Google Scholar
• Zhou J, Fa H, Yin W, Zhang J, Hou C, Huo D, et al. 2014. Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer's disease. Mater Sci Eng C Mater Biol Appl. 37: 348–355.
   PubMed Web of Science ®Google Scholar